Maureen Dubreuil

Maureen Dubreuil

Auto-generated profile, based on publicly available information

Maureen Dubreuil

Section of Rheumatology, Boston University School of Medicine, Boston, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2019 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PDF file
MWMichael M. Ward
Michael M. Ward
ADAtul Deodhar
Atul Deodhar
LGLianne S. Gensler
Lianne S. Gensler
MDMaureen Dubreuil
Maureen Dubreuil
DYDavid Yu
David Yu
LCLiron Caplan
Liron Caplan
Objective: To update evidence‐based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA).Methods: We conducted updated systematic literature reviews for 20 clinical questions on pharmacologic treatment addressed in the 2015 guidelines, and for 26 new questions on pharmacologic treatment, treat‐to‐target strategy, and use of imaging. New questions addressed the use of secukinumab, ixekizumab, tofacitinib, tumor necrosis factor inhibitor (TNFi) biosimilars, and biologic tapering/discontinuation, among others. We used the Grading of Recommendations, Assessment, Development and Evaluation methodology to assess the quality of evidence and formulate recommendations and required at least 70% agreement among the voting panel.Results: Recommendations for AS and nonradiographic axial SpA are similar. TNFi are recommended over secukinumab or ixekizumab as the first biologic to be used. Secukinumab or ixekizumab is recommended over the use of a second TNFi in patients with primary nonresponse to the first TNFi. TNFi, secukinumab, and ixekizumab are favored over tofacitinib. Co‐administration of low‐dose methotrexate with TNFi is not recommended, nor is a strict treat‐to‐target strategy or discontinuation or tapering of biologics in patients with stable disease. Sulfasalazine is recommended only for persistent peripheral arthritis when TNFi are contraindicated. For patients with unclear disease activity, spine or pelvis magnetic resonance imaging could aid assessment. Routine monitoring of radiographic changes with serial spine radiographs is not recommended.Conclusion: These recommendations provide updated guidance regarding use of new medications and imaging of the axial skeleton in the management of AS and nonradiographic axial SpA.

21 August 2019 in Arthritis Care & Research
Verified
Journal Article
Open access
PDF file
MWMichael M. Ward
Michael M. Ward
ADAtul Deodhar
Atul Deodhar
LGLianne S. Gensler
Lianne S. Gensler
MDMaureen Dubreuil
Maureen Dubreuil
DYDavid Yu
David Yu
LCLiron Caplan
Liron Caplan
Objective: To update evidence‐based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA).Methods: We conducted updated systematic literature reviews for 20 clinical questions on pharmacologic treatment addressed in the 2015 guidelines, and for 26 new questions on pharmacologic treatment, treat‐to‐target strategy, and use of imaging. New questions addressed the use of secukinumab, ixekizumab, tofacitinib, tumor necrosis factor inhibitor (TNFi) biosimilars, and biologic tapering/discontinuation, among others. We used the Grading of Recommendations, Assessment, Development and Evaluation methodology to assess the quality of evidence and formulate recommendations and required at least 70% agreement among the voting panel.Results: Recommendations for AS and nonradiographic axial SpA are similar. TNFi are recommended over secukinumab or ixekizumab as the first biologic to be used. Secukinumab or ixekizumab is recommended over the use of a second TNFi in patients with primary nonresponse to the first TNFi. TNFi, secukinumab, and ixekizumab are favored over tofacitinib. Co‐administration of low‐dose methotrexate with TNFi is not recommended, nor is a strict treat‐to‐target strategy or discontinuation or tapering of biologics in patients with stable disease. Sulfasalazine is recommended only for persistent peripheral arthritis when TNFi are contraindicated. For patients with unclear disease activity, spine or pelvis magnetic resonance imaging could aid assessment. Routine monitoring of radiographic changes with serial spine radiographs is not recommended.Conclusion: These recommendations provide updated guidance regarding use of new medications and imaging of the axial skeleton in the management of AS and nonradiographic axial SpA.

1 April 2020 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
PDF file
PKParas Karmacharya
Paras Karmacharya
ADAli Duarte‐Garcia
Ali Duarte‐Garcia
MDMaureen Dubreuil
Maureen Dubreuil
MMM. Hassan Murad
M. Hassan Murad
RSRavi Shahukhal
Ravi Shahukhal
JDJohn M. Davis
John M. Davis

1 August 2018 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
MDMaureen Dubreuil
Maureen Dubreuil
QLQiong Louie-Gao
Qiong Louie-Gao
CPChristine E Peloquin
Christine E Peloquin
HCHyon K Choi
Hyon K Choi
YZYuqing Zhang
Yuqing Zhang
TNTuhina Neogi
Tuhina Neogi
Objectives Spondyloarthritis (SpA) is associated with an increased risk of myocardial infarction (MI) due to underlying inflammation and possibly due to medications such as certain non-steroidal anti-inflammatory drugs (NSAIDs). We sought to describe MI risk among patients with SpA who were prescribed NSAIDs, and to compare the pattern of risk in SpA with that in osteoarthritis (OA). Methods Nested case-control studies were performed using The Health Improvement Network (THIN). Underlying cohorts included adults with incident SpA or OA who had >1 NSAID prescription and no history of MI. Within each cohort, we matched each MI case to four controls without MI. NSAID use was categorised as: (a) current (prescription date 0–180 days prior to index date), (b) recent (181–365 days) or (c) remote (>365 days). We performed conditional logistic regression to compare the odds of current or recent NSAID use relative to remote use of any NSAID, considering diclofenac and naproxen specifically. Results Within the SpA cohort of 8140 and the OA cohort of 244 339, there were 115 and 6287 MI cases, respectively. After adjustment, current diclofenac use in SpA was associated with an OR of 3.32 (95% CI 1.57 to 7.03) for MI. Naproxen was not associated with any increase (adjusted OR 1.19, 95% CI 0.53 to 2.68). A ratio of ORs for SpA/diclofenac relative to OA/diclofenac was 2.64 (95% CI 1.24 to 5.58). Conclusions MI risk in SpA is increased among current users of diclofenac, but not naproxen. The MI risk with diclofenac in SpA appears to differ from that in OA.

13 January 2016 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
MDMaureen Dubreuil
Maureen Dubreuil
CPChristine Peloquin
Christine Peloquin
YZYuqing Zhang
Yuqing Zhang
HCHyon K. Choi
Hyon K. Choi
RIRobert Davies Inman
Robert Davies Inman
TNTuhina Neogi
Tuhina Neogi

1 August 2021 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
EMElana Meer
Elana Meer
TTTelma Thrastardottir
Telma Thrastardottir
XWXingmei Wang
Xingmei Wang
MDMaureen Dubreuil
Maureen Dubreuil
YCYong Chen
Yong Chen
AOAlexis Ogdie
Alexis Ogdie
Objective: To compare potential risk factors for the diagnosis of psoriatic arthritis (PsA), psoriasis (PsO), rheumatoid arthritis (RA), and ankylosing spondylitis (AS).Methods: Four parallel case-control studies were conducted within The Health Improvement Network using data between 1994 and 2015. Patients with PsA, PsO, RA, or AS were identified using validated code lists and matched to controls on age, sex, practice, and year. Risk factors were selected in the time prior to diagnosis. Multivariable logistic regression models were constructed for each disease using automated stepwise regression to test potential risk factors.Results: Patients with incident PsA (n = 7594), PsO (n = 111,375), RA (n = 28,341), and AS (n = 3253) were identified and matched to 75,930, 1,113,345, 283,226, and 32,530 controls, respectively. Median diagnosis age was 48 (IQR 38–59), 43 (IQR 28–60), 60 (IQR 48–71), and 41 (IQR 32–54) years, respectively. In multivariable models, there were some shared and some differing risk factors across all 4 diseases: PsA was associated with obesity, pharyngitis, and skin infections; PsA and PsO were associated with obesity and moderate alcohol intake; PsA and AS were associated with uveitis; and PsA and RA were associated with preceding gout. Both RA and AS were associated with current smoking, former moderate drinking, anemia, osteoporosis, and inflammatory bowel disease. All shared former or current smoking as a risk factor; statin use was inversely associated with all 4 diseases.Conclusion: Shared and different risk factors for PsA, PsO, RA, and AS were identified. Statin use was inversely associated with all 4 conditions.